TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02421484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic mesenchymal stromal cells
Description: The allogeneic mesenchymal stromal cells will be administered intravenously.
Study: NCT00906841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 90Y-DOTA-hLL2
Description: Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
Study: NCT01973660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Letrozole or tamoxifen will be prescribed according to patient's menopausal status

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Only administrated if tumor progression is observed by US on week 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Only administrated if tumor progression is observed by US on week 6
Study: NCT02548455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quartet 1457Q LV Lead
Study: NCT03881306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-TACE
Description: D-TACE with CalliSpheres-Oxaliplatin
Study: NCT03568266

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of saliva
Study: NCT03357874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg loading dose of clopidogrel as pretreatment followed by 75 mg daily for 12 months (52 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: patients will receive a 180 mg loading dose as pretreatment of PCI followed by 90 mg bi-daily for 12 months (52 weeks).
Study: NCT04022200

Intervention type: DEVICE
Intervention: Paclitaxel DCB
Description: The length of the DCB catheter should be chosen to exceed the target lesion for at least 2mm (at both proximal and distalends). The catheter(s) will be inflated for 30 to 60s with a minimum of 7 atm. Predilation of the diseased coronary segment with a uncoated balloon/scoring balloon/cutting balloon before the use of DCB will be encouraged. DES should be implanted if the angiographic result after DCB alone therapy is not satisfactory due to significant recoil/residual stenosis or dissection (Type C-F).
Study: NCT00464815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One intramuscular dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One subcutaneous dose
Study: NCT04184726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: mindfulness and cognitive behavioural therapy techniques taught in group sessions meeting once weekly for 8 weeks, and home practice between sessions.
Study: NCT04237571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CANE Meal Program
Description: Participants will be encouraged to pick up a healthy meal from the Community Agriculture Nutritional Experience (CANE) Kitchen in Whitesburg, Kentucky once a week for five weeks. The meals will consist of at least one serving of a fruit or a vegetable. At each meal, education materials will be distributed, including the recipe for the healthy meals and nutrition handouts that are linked to the recipes. Additional information about the ways the nutrients in the meal may help protect from the negative effects of environmental pollutants will be included.
Study: NCT01517763

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional CPAP Therapy
Description: HC244 devices without Thermosmart or SensAwake

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed pressure ICON™ without ThermoSmart™
Description: Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto ICON™ with SensAwake™ and ThermoSmart™
Description: APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
Study: NCT00542399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir (insulin detemir)
Description: Levemir once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levemir twice a day
Description: Levemir twice a day
Study: NCT02112630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2a
Description: P-IFN alfa 2b 0.75 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2a
Description: P-IFN alfa 2b 0.75 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2b
Description: P-IFN alfa 2a 135 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-IFN alfa 2b
Description: P-IFN alfa 2a 135 mcg/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg PO once daily or 200 mg PO three times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 200 mg PO once daily or 200 mg PO three times a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg PO three times daily starting at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: 800 mg PO three times daily starting at week 4
Study: NCT03024957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
Study: NCT01564134

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine
Description: hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
Study: NCT03024957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
Study: NCT01017133

Intervention type: RADIATION
Group type: OTHER
Intervention: fludeoxyglucose F 18
Description: Given IV

Intervention type: RADIATION
Group type: OTHER
Intervention: Fluorine F 18 EF5
Description: Given IV

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Positron emission tomography
Description: Undergo scan
Study: NCT02196441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% tetracaine local anaesthetic drops
Description: topical anaesthetic drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
Study: NCT02893033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: rTMS
Study: NCT01732640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
Study: NCT03236961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: P.o. moxifloxacin 400 mg x1 for 7 days
Study: NCT01437254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPERT
Description: Single 340 MBq CPERT scan in first 10 subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GPERT
Description: Single 340 MBq GPERT scan in up to 20 case-matched controls
Study: NCT02395848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: 200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
Study: NCT03193320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy protocol
Description: Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid therapy protocol
Description: Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy protocol
Description: Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
Study: NCT04266834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: First, these providers will receive educational materials (e.g. a slide deck and one-page fact sheet) meant to mimic what physicians will receive in the real-world market as they learn about the Hikari DX L-FABP test.~Second, within each of their second-round cases, intervention-arm physicians only will receive simulated test results from the L-FABP test at the clinically-appropriate point in each case.
Study: NCT02497820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).~Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.~The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place.
Study: NCT01927536

Intervention type: DEVICE
Intervention: White LED Flashlight
Description: white light setting

Intervention type: DEVICE
Intervention: Red/Green Green Dominant LED Flashlight
Description: Green LED light dominant setting
Study: NCT03709368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAST
Description: PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAST
Description: PHAST sessions are based on the 'PHAST step-by-step guide: A participatory approach for the control of diarrhoeal disease' of the World Health Organization. Considering the overlap with some CLTS activities, only a selection of the full guideline will be enrolled, namely: 1) Health problems in our community, 2) Good and bad hygiene behaviors, 3) Investigating community practices, 4) How diseases spread, 5) Blocking the spread of disease, 6) Selecting the barriers, 7) Choosing sanitation improvements, and 8) Choosing improved hygiene behaviors. These 8 activities will be enrolled in approximately 40 community groups. Each activity will take between 30 minutes - 2 hours to complete.
Study: NCT01409850

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aqualizer
Description: The Aqualizer is a soft splint with water-filled pads.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft splint
Study: NCT03709368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RANAS
Description: Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of these add-on visits is based on the RANAS manual: 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). First, baseline data is gathered through a questionnaire to better understand the context that is at play. Next, this data is analyzed in a do'er non-do'er analysis. Only those behavioral factors that are significantly different between do'ers and non-do'ers will be included in the intervention, as these are, at least theoretically, considered to be decisive for HW and latrine use behavior in the current setting.
Study: NCT00322556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulins Intravenous (Human)
Description: Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
Study: NCT00838474

Intervention type: OTHER
Group type: OTHER
Intervention: music
Description: Each infant was randomized to receive music therapy or no music over 2 consecutive days
Study: NCT01446913

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP Intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced CPAP Intervention
Study: NCT03709368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mini-RANAS
Description: Nine household visits of 20-40 min each will be offered at a frequency of one visit every two months. The content of the mini-RANAS add-on intervention is based on the 'Norm Behavior Change Techniques' from the RANAS manual 'Systematic Behavior Change in Water, Sanitation and Hygiene - A practical guide to using the RANAS approach' (www.ranasmosler.com). During the mini-RANAS household visits, emphasis will be put on norms and volunteers will encourage participants to become a role model by improving HW and sanitation infrastructure and behavior.
Study: NCT01021150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombrabulin (AVE8062)
Description: Pharmaceutical form:injection solution~Route of administration: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Pharmaceutical form: injection solution~Route of administration: intravenous infusion
Study: NCT02621515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
Study: NCT00860028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Varenicline Pretreatment
Description: 4 weeks varenicline (Chantix) titrated to 1 mg oral tablet twice per day before the smoking quit date followed by 4 weeks varenicline (Chantix) 1 mg oral tablet twice per day treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term Varenicline Pretreatment
Description: 3 weeks placebo + 1 week varenicline (Chantix)pretreatment + 4 weeks varenicline 1 mg oral tablet twice per day treatment following the smoking quit date.
Study: NCT04058483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotizability testing
Description: Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnotizability testing
Description: Hypnotizability testing in-person vs. by phone. All participants will complete both conditions.
Study: NCT01725477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylen blue &normal saline
Description: Washing after dye injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylene blue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metheylne blue with normal saline
Study: NCT03974633

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection
Description: All information is included in the Arm/group descriptions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection
Description: All information is included in the Arm/group descriptions

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Injection
Description: All information is included in the Arm/group descriptions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Injection
Description: All information is included in the Arm/group descriptions
Study: NCT01754259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
Study: NCT03154320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same-Day Treatment
Description: Treatment with ART or TB medication on day of HIV diagnosis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment
Study: NCT01007916

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B contact lens
Description: Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
Study: NCT03709368

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo poster
Description: One household visit will be offered. During this visit, a placebo poster will be distributed focusing on first aid. The topics to be discussed are burns, cuts and grazes. The main goal of this household visit is to avoid jealousy among the control cohort.
Study: NCT01007916

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lens
Description: Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.